Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
INE. Anuario estadístico de España. Principales causas de fallecimientos según CIE; 2002. Disponible en: http://www.ine.es/prodyser/pubweb/anuario05/anu05_5salud.pdf.
[2.]
World Health Organization (WHO). World Health Report; 2000.
[3.]
Instituto de información sanitaria. Barómetro Sanitario 2003. Resultados generales. Disponible en: http://www.msc.es/Diseno/sns/sns_sistemas_informacion.htm
[4.]
Memoria del Instituto Nacional de Gestión Sanitaria (INSALUD). Madrid: Ministerio de Sanidad y Consumo; 2000. Disponible en: http://www.msc.es/insalud/home.htm
[5.]
OECD Health data base 2003 [consultado 8/2003]. Disponible en: www.oecd.org
[6.]
S.N.S. Observatorio.
Informe anual del Sistema Nacional de Salud 2003.
Ministerio de Sanidad y Consumo, (2004),
[7.]
J. Puig-Junoy.
¿Es la fi nanciación sanitaria sufi ciente y adecuada?.
Gac Sanit, 20 (2006), pp. 96-102
[8.]
R. Rodríguez-Monguió, F. Antoñanzas.
Healthcare rationing in Spain. Framework, descriptive analysis and consequences.
Pharmacoeconomics, 24 (2006), pp. 537-548
[9.]
F. Antoñanzas, R. Rodríguez, J.A. Sacristán, R. Illa.
Los medicamentos en la Unión Europea: el tándem comercio-salud.
Gac Sanit, 19 (2005), pp. 151-167
[10.]
Biotechnology Medicines in Development, Report 2006. Disponible en: http://www.allhealth.org/BriefingMaterials/PhRMA418BiotechMeds-415.pdf
[11.]
Biotechnology medicines in development, Report 2008. Disponible en: http://www.phrma.org/fi les/Biotech %202008.pdf
[12.]
N.M. Kuderer, D.C. Dale, J. Crawford, et al.
Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.
Cancer, 106 (2006), pp. 2258-2266
[13.]
V. Caggiano, R.V. Weiss, T.S. Rickert, W.T. Linde-Zwirble.
Incidence, cost and mortality of neutropenia hospitalization associated with chemotherapy.
Cancer, 103 (2005), pp. 1916-1924
[14.]
J. Douglas Rizzo, M.R. Somerfi eld, K.L. Hagerty.
Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice Guideline Update.
Journal of Clinical Oncology, 26 (2008),
[15.]
C. Bokemeyer, M.S. Aapro, A. Courdi.
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update.
European Journal of Cancer, 43 (2007), pp. 258-270
[16.]
Cancer –and chemotherapy– induced anemia. NCCN Clinical Practice Guidelines in Oncology. 2009; 3.
[17.]
G.H. Lyman, N.M. Kuderer, Djulbegovic B.
Prophylactic granulocyte colony-stimulating factor in patients receiving dose-intensive cancer chemotherapy: a meta-analysis.
Am J Med., 112 (2006), pp. 406-411
[18.]
N.M. Kuderer, D.C. Dale, J. Crawford, G.H. Lyman.
Impact or primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review.
J Clin Oncol., 25 (2007), pp. 3158-3167
[19.]
European Medicines Agency (EMEA). European Public Assessment Report for Ratiograstim®(H-C-825).
[20.]
European Medicines Agency (EMEA). Guideline on Similar Biological Medicinal Products Containing Biotechnology-Derived Proteins as Active Substance. Non-Clinical and Clinical Issues. EMEA/CHMP/BWP/42832/2005.
[21.]
European Medicines Agency (EMEA). Guideline on Similar Biological Medicinal Products. CHMP/437/04.
[22.]
European Commission. Volume 2A. Procedures for Marketing Authorisation. Chapter 4. Centralised Procedure.
[23.]
EMEA/CHMP/96268/2005.
[24.]
Who Informal Consultation on International Non-proprietary Names (INN)? Policy for Biosimilar Products. INN Working Document 07.211.
Copyright © 2010. Sociedad Española de Farmacia Hospitalaria
